Create a FREE Provider account to access the eLearning Modules.Register for the Curriculum
QUESTIONS or TECHNICAL ISSUES?
Contact: 202-232-6749 or Opioids@HealthHIV.org
How to Access the Courses
- Step 1: Register for the Curriculum
- All participants must register for the curriculum to gain access to the courses
- Click the “Register for the Curriculum” button above
- Complete the form fields to register for the curriculum and create an account
- Click “Submit”
- If you already have an account: Click “Log-in” at the top right of the form. Complete the form if you are prompted to – this will register your account for the curriculum. Click “Submit”.
- Step 2: Access Individual Courses
- After you have registered for the curriculum by following the steps above, you can access the modules by either:
- Logging in to the learning management system and finding the courses under “Learning”, or
- Returning to this page, selecting one of the courses below, and clicking “Open Course”
- After you have registered for the curriculum by following the steps above, you can access the modules by either:
Target Audience
This activity is intended for physicians, physician assistants, pharmacists, registered nurses, social workers and other healthcare providers engaged in the care of patients with opioid use disorder.
Educational Objectives
After completing this activity, the participant should be better able to:
- ModuleLearning ObjectivesAccreditation Details
- Acupuncture, Massage, and Self-Care
Open this module→- Explain the risks and benefits of acupuncture and massage therapies
- Explain the role of acupuncture and massage in comprehensive pain management
- Name three (3) conditions for which acupuncture is recommended in practice guidelines
- Describe two (2) self care techniques
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2368-H01-P
Knowledge - After the Waiver: Translating Training Into Practice, Advanced Topics in Buprenorphine
Open this module→- Simplify the buprenorphine induction process to make it feasible in their practice
- Address difficulties that may occur over the course of treating patients with buprenorphine
- Develop psychosocial treatment plans that are tailored to patient needs
- Manage unanticipated events such as injury and pregnancy in patients on buprenorphine
- Name two (2) resources that can provide additional support for buprenorphine prescribers as they encounter complexities in patient care
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2369-H01-P
Application - Cognitive Behavioral Therapy (CBT) & Mind-Body Techniques in Addressing Pain
Open this module→- List three (3) mind body strategies that are helpful for pain patients
- Instruct a patient in one breathing exercise
- Describe central sensitization and indicate three (3) risk factors that predispose an individual to it
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2370-H01-P
Application - Development and Implementation of Evidence-Based Opioid Prescribing Guidelines for Surgical Patients
Open this module→- Summarize the risks and benefits of opioids prescribed for acute surgical pain
- Evaluate the existing CDC opioid prescribing guidelines in light of current evidence
- Describe Mayo Clinic’s historical surgical prescribing practices and patient-reported opioid consumption
- Recognize how multidisciplinary teams developed and implemented prescribing guidelines
- Describe how to access the publicly-available Mayo Clinic guidelines for opioid prescribing at discharge from surgery
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2371-H01-P
Knowledge - Enhancing Organizational Capacity and Provider Readiness to Treat OUD With Buprenorphine/Naloxone: Clinical Application of a MOUD
Open this module→- Detail how to treat OUD with buprenorphine/naloxone
- List at least two justifications for the use of combination buprenorphine/naloxone as the standard of care for general use
- List at least three methods for establishing community partnerships and promoting MOUD services in general medical settings
- Describe the key principles of the medication first model
- Discuss the benefit of adding psychosocial support to the treatment of patients receiving MOUD
- Employ appropriate urine toxicology strategies
- Outline treatment considerations for patients with co-occurring psychiatric disorders
- Explain how to conduct a Telehealth session for treatment of OUDs
November 2, 2020Expiration Date:
November 1, 2021
UAN #:
JA4008162-9999-20-2407-H01-P
Application - Enhancing Organizational Capacity and Provider Readiness to Treat OUD With Buprenorphine/Naloxone: System Level Strategies
Open this module→- List at least four overlapping characteristics of successful MOUD models of care
- Describe the necessary organizational and clinical changes needed to address drug
use in primary care settings - Apply the roadmap (plan, do, study, act) to implement quality improvement processes
for each of the five key clinical changes necessary in addressing substance use
disorders - Differentiate between language and phrasing that focused on the person from disease-
based language - Address workflow considerations in the identification and management of OUDs
- Discuss the role of motivational interviewing in addressing the treatment of OUDs
with patients - Define the collaborative care model
October 22, 2020Expiration Date:
October 21, 2021
UAN #:
JA4008162-9999-20-2406-H01-P
Application - Epidemiology of OUD: the US and the District
Open this module→- Describe the current spread of opioid use and overdoses across the US and within the District
- Detail the common demographics of people living with OUD in DC
- List the main drugs utilized by people living with OUD
- Explain the regional needs for services for people living with OUD
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2372-H01-P
Knowledge - Harm Reduction Approaches for Providers Addressing Opioid Use
Open this module→- Define Harm Reduction
- Identify factors that impact patient-provider relationships
- Describe Harm Reduction techniques for patient-centered clinical conversations
- Identify specific Harm Reduction strategies for patients who use opioids
- Apply Harm Reduction strategies to a case scenario
Activity Release Date:
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2373-H01-P
Knowledge - Implementing the 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain
Open this module→- Describe the historical background and rationale for the CDC chronic opioid guidelines
- Discuss when to initiate, continue or discontinue opioids for chronic pain
- Plan how to select an opioid, dose, and follow persons on chronic opioid treatment
- Outline strategies for risk assessment and addressing harms of opioid use
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2374-H01-P
Knowledge - Integrating Buprenorphine Treatment Into Infectious Disease Settings
Open this module→- Relate the epidemiology of opioid use disorder (OUD) and impact on infectious disease epidemics
- Describe the use of medication treatment for OUD (MOUD) for treatment of OUD and importantly the use of buprenorphine
- Discuss the considerations for the management of OUD and infectious disease treatment
- Review the NASEM recommendations published January 2020 to address barriers to integration of infectious disease and OUD prevention and treatment services
October 28, 2020Expiration Date:
October 27, 2021
UAN #:
JA4008162-9999-20-2435-H01-P
Knowledge - Nutrition for Pain Management
Open this module→- Discuss three dietary changes that will benefit pain patients
- Discuss two changes in physiology that enable dietary modifications to improve health and pain
- Counsel patients on preliminary dietary changes for pain
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2375-H01-P
Application - Opioid Overdose Prevention & Naloxone Education
Open this module→- Name three (3) historical events in the history of opioid use
- Describe the basic profile of opioids
- Describe the pharmacology of naloxone
- Name the laws protecting individuals from civil liability associated with naloxone administration and the reporting an overdose
- Summarize the epidemiology of opioid overdoses in the District of Columbia
- Indicate the importance of contacting emergency medical services
- Administer naloxone properly to reverse a known or suspected overdose
- List steps on how to care for an individual after the administration of naloxone
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2376-H01-P
Application - Patient-Provider Relationship in Addressing Addiction
Open this module→- Name the three important areas of consideration when addressing opioid use
- Name at least two challenges to address opioid disorders with patient
- Elaborate on at least two types of provider-patient relationships
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2377-H01-P
Knowledge - Treating Acute Pain to Improve Outcomes and Reduce Opioids
Open this module→- List the relative effectiveness of common pain medications
- Indicate the common side effects of available pain medications
- Describe the public health effects and costs of opioid prescriptions for acute pain
- Identify the four (4) main mechanisms of pain and their impact on acute pain
- Differentiate outcomes between common pain medications and opioid medications in managing acute pain
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2378-H01-P
Knowledge - Treating Opioid Use Disorder: Primer for Clinicians
Open this module→- Explain the chronic disease model of opioid use disorder (OUD)
- Discuss the risks and benefits of medications that are available to treat OUD
- Describe the fundamentals of medications treatment for OUD
- Begin to develop partnerships with local substance use treatment programs
- Choose a buprenorphine waiver training program that fits their needs and the needs of their patients
October 8, 2020Expiration Date:
October 7, 2021
UAN #:
JA4008162-9999-20-2379-H01-P
Knowledge - Treatment Considerations for Co-Occurring Opioid and Stimulant Use
Open this module→- Describe the clinical implications of stimulant use by individuals with opioid use
disorder (OUD) - Utilize strategies for detecting clinically significant stimulant use by patients in
treatment for OUD - Identify elements of treatment plans that are tailored to the needs of patients with
stimulant use - Employ strategies to address difficulties that may occur over the course of treating
patients with stimulant use
October 22, 2020Expiration Date:
October 21, 2021
UAN #:
JA4008162-9999-20-2408-H01-P
Application - Describe the clinical implications of stimulant use by individuals with opioid use
Faculty
Diana Coffa, MD
John Dombrowski, MD
Heather Tick, M.A., M.D., CCFP
Debra Gordon, RN, DNP, FAAN
Don Teater, MD
Jenifer Jackson, MS
Rebecca Vargas-Jackson, MD
Brian Hurley, MD, MBA, DFASAM
David Gorelick, MD, PhD, DLFAPA, FASAM
Sandra Springer, MD
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HealthHIV. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ per module. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education per module.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours (per module).
CPH Credit
Postgraduate Institute for Medicine (PIM) is an approved provider of CPH Recertification Credits by the National Board of Public Health Examiners. Public health professionals will receive 1.0 CPH credits (per module) for participating in this activity.
AAPA Credit Designation Statement
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 10/7/2021. PAs should only claim credit commensurate with the extent of their participation.
Social Worker Education
As a Jointly Accredited Organization, Postgraduate Institute for Medicine is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Postgraduate Institute for Medicine maintains responsibility for this course. Social workers completing this course receive 1.0 Clinical continuing education credits (per module).
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty
David Gorelick, MD, PhD, DLFAPA, FASAM
Royalty: Wolters Kluwer (UpToDate)
Consulting Fees: BloomingMind LLC
Honoraria: Springer Nature, Western IRB
All other faculty members have nothing to disclose.
Planners and Managers
The PIM planners and managers have nothing to disclose. The HealthHIV planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. Participants must read the learning objectives, faculty disclosures, and complete each educational activity. Once each activity is completed, you must pass the post-test with a score of 80% or better, and complete the online evaluation form. Upon successful completion of each activity, you will be provided an immediate certificate to download or print for your files.
For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
For questions about the accreditation of this activity, please visit www.pimed.com
Media
Internet
Computer System Requirements
Participants need access to a phone, computer, or tablet with audio and video capabilities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
